Ardevora Asset Management LLP Has $10.61 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Ardevora Asset Management LLP trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 47.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,106 shares of the medical research company's stock after selling 124,323 shares during the period. Ardevora Asset Management LLP's holdings in Edwards Lifesciences were worth $10,607,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB lifted its position in Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company's stock valued at $123,261,000 after buying an additional 1,488,791 shares in the last quarter. Telos Capital Management Inc. raised its stake in shares of Edwards Lifesciences by 158.2% during the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company's stock valued at $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC raised its stake in shares of Edwards Lifesciences by 5,092.4% during the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company's stock valued at $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP raised its stake in shares of Edwards Lifesciences by 83.3% during the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company's stock valued at $311,000 after purchasing an additional 2,043 shares during the period. Finally, HealthInvest Partners AB purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $1,587,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Citigroup lifted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. StockNews.com lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Wednesday, March 20th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research note on Thursday, March 7th. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a report on Monday, April 15th. Finally, Mizuho upped their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a "buy" rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $91.73.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.51 on Friday, reaching $85.94. 3,895,701 shares of the company's stock were exchanged, compared to its average volume of 2,826,513. The firm has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 4.26 and a beta of 1.05. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The business's 50-day moving average is $90.15 and its two-hundred day moving average is $78.42. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts' consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 earnings per share. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company's stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.